New Strategies in the Discovery of Novel Non-Camptothecin Topoisomerase I Inhibitors
Authors: Sheng, Chunquan; Miao, Zhenyuan; Zhang, Wannian
Source: Current Medicinal Chemistry, Volume 18, Number 28, October 2011 , pp. 4389-4409(21)
Publisher: Bentham Science Publishers
Abstract:Topoisomerase I (Top1) represents an important target of active interest in developing novel anticancer agents. Camptothecin derivatives are the only class of clinically approved Top1 inhibitors and show potent efficacy in anticancer therapy. However, there are also several major limitations for them, such as poor chemical stability, drug resistance, long infusions and side effects. To overcome the drawbacks of the camptothecins, the discovery of non-camptothecin Top1 inhibitors has recently emerged as a promising field to find better antitumor agents. Non-camptothecin Top1 inhibitors are expected to possess better chemical stability, different therapeutic activities and antitumor spectrum, improved pharmacokinetics and lower toxicity. This review focuses on various strategies that were used in the discovery of non-camptothecin Top1 inhibitors. In particular, the chemical scaffolds, structure-activity relationships and binding modes of the newly identified non-camptothecin Top1 inhibitors are discussed in detail.
Document Type: Research Article
Publication date: October 1, 2011
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.